Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Oncogenesis Inc. currently manages 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This active matter is assigned to 1 distinct examiner, M FRANCO G SALVOZA. The prosecution is concentrated in 1 distinct art unit, reflecting a specific area of technical inquiry for the organization. M FRANCO G SALVOZA is the busiest examiner, overseeing 1 pending office action.
This 1 pending office action is the only current requirement for the portfolio. The presence of 1 distinct examiner and 1 distinct art unit simplifies the coordination of prosecution efforts. The busiest examiner's workload of 1 pending office action is equal to the total number of pending actions for the company. Practitioners should note the centralized nature of this prosecution, as all current activity is funneled through a single examiner. This single point of contact within 1 distinct art unit facilitates a more predictable interaction with the patent office. The current data suggests a targeted approach to securing intellectual property in the biotechnology sector.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SALVOZA, M FRANCO G | 1 | 68.4% | +30.0% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17956078 | CRISPR ASSAY FOR RAPID, ENHANCED SCREENING OF HPV-RELATED DISEASE | SALVOZA, M FRANCO G | 34d |
| Art Unit | Apps |
|---|---|
| 1672 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17956078 | CRISPR ASSAY FOR RAPID, ENHANCED SCREENING OF HPV-RELATED DISEASE | SALVOZA, M FRANCO G | 1672 | §103 | Non-Final OA | 34d | Pending | Sep 29, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial